Faculty of Medicine and Health Sciences: Research Development and Support 8 Mei 2018 (#14)

[Click on blue <u>hyperlink</u> for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit <u>www.grants.nih.gov</u>.

Confirm your intent to apply ASAP, but not later than 30 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

Important Notices:

- Clarification of NIHs Policy Regarding a Change in Program Directors/Principal Investigators Status (NOT-OD-18-172) Office of the Director, NIH
- Findings of Research Misconduct (NOT-OD-18-173) Office of the Director, NIH

1. Strengthen Regulatory Systems to Ensure the Safety and Quality of Food and Medical Products

Letter of Intent: 30 days prior to the application due date

Application Due Date: July 2, 2018, by 11:59 PM Eastern Time.

Funding Opportunity Announcement: U.S. Food and Drug Administration (<u>FDA</u>). NOTE: The policies, guidelines, terms, and conditions stated in this announcement may differ from those used by the NIH. Where this Funding Opportunity Announcement (FOA) provides specific written guidance that may differ from the general guidance provided in the grant application form, please follow the instructions given in this FOA. The FDA does not follow the NIH Page Limitation Guidelines or the NIH Review Criteria. Applicants are encouraged to consult with FDA Agency Contacts for additional information regarding page limits and the FDA Objective Review Process.

The Cooperative Agreement announced in this FOA represents the continuation and further refinement as well as expansion of well-established collaborations between WHO and FDA, through OIP, in support of data-driven and science-based public health, science-based and research strategies and approaches that align well with FDA domestic and global goals. This cooperative agreement is expected to contribute to the knowledge base of the current regulatory efforts in support of food and medical products safety and quality globally and address specific challenges and fill gaps in the global efforts to ensure said safety and quality of such products. Relevant strategies include: 1) developing global norms and standards; 2) articulating evidence-based and science-based policy options, including those relating to regulatory systems performance; and 3) providing technical support to national regulatory authorities and governments through systems strengthening, research, public health and scientific efforts.

Budget: Award(s) will provide one (1) year of support and include future recommended support for five (4) additional year(s) contingent upon annual appropriations, availability of funding and satisfactory awardee performance.FDA/OC/OIP intends to fund up to \$1,500,000, for fiscal year 2018 in support of this grant program. It is anticipated that up to one award will be made, not to exceed (a ceiling of) \$4,500,000 in total costs (direct plus indirect), over the possible 5- year course of the cooperative agreement. Application budgets need to reflect the actual needs of the proposed project and should not exceed the following in total costs (direct and indirect): YR 01: \$1,500,000. YR 02: \$750,000. YR 03: \$750,000. YR 04: \$750,000. YR 05: \$750,000

2. Identification and Management of Behavioral Symptoms and Mental Health Conditions in Individuals with Intellectual Disabilities

Letter of Intent: 30 days prior to the application due date

Hyperlink: (PAR-18-766)

Hyperlink: (RFA-FD-18-022)

Type: *R01*

Type: *U01*

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages research grant applications focusing on identification and management of behavioral symptoms and mental health conditions in individuals with intellectual disabilities (ID). Specific areas of interest for this funding opportunity are (1) applications to develop and validate assessment tools that reliably identify behavioral symptoms or diagnose mental health conditions in individuals with ID, and (2) applications studying the pharmacokinetics, safety and efficacy of specific psychotropic medications for treatment of behavioral symptoms or mental health conditions in individuals with ID.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

3. BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: (RFA-MH-19-136)

Type: RO2

Application Due Date: September 27, 2018; September 6, 2019; September 9,2020Apply by 5:00 PM local time of applicant organization. Funding Opportunity Announcement: The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis of com plex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.

Budget: Issuing IC and partner components intend to commit an estimated total of \$8 million to fund 6-9 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

Brief definitions of some NIH grant mechanisms: comprehensive list of extramural grant and cooperative agreement activity codes

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University

5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: *Dr Christa Coetsee* • Tel: 9838 • Email: cde vries@sun.ac.za